JP6836510B2 - 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 - Google Patents

少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 Download PDF

Info

Publication number
JP6836510B2
JP6836510B2 JP2017546034A JP2017546034A JP6836510B2 JP 6836510 B2 JP6836510 B2 JP 6836510B2 JP 2017546034 A JP2017546034 A JP 2017546034A JP 2017546034 A JP2017546034 A JP 2017546034A JP 6836510 B2 JP6836510 B2 JP 6836510B2
Authority
JP
Japan
Prior art keywords
nanoparticles
pharmaceutical compound
biocompatible
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504450A5 (enExample
JP2018504450A (ja
Inventor
ジェルマン，マチュー
メイル，マリー−エディット
ポティエ，アニエス
レヴィ，ローラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curadigm SAS
Original Assignee
Curadigm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm SAS filed Critical Curadigm SAS
Publication of JP2018504450A publication Critical patent/JP2018504450A/ja
Publication of JP2018504450A5 publication Critical patent/JP2018504450A5/ja
Application granted granted Critical
Publication of JP6836510B2 publication Critical patent/JP6836510B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017546034A 2014-11-25 2015-11-24 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 Active JP6836510B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306874 2014-11-25
EP14306874.0 2014-11-25
PCT/EP2015/077446 WO2016083343A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

Publications (3)

Publication Number Publication Date
JP2018504450A JP2018504450A (ja) 2018-02-15
JP2018504450A5 JP2018504450A5 (enExample) 2019-01-31
JP6836510B2 true JP6836510B2 (ja) 2021-03-03

Family

ID=52013981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546034A Active JP6836510B2 (ja) 2014-11-25 2015-11-24 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用

Country Status (13)

Country Link
US (2) US10391058B2 (enExample)
EP (1) EP3229776B1 (enExample)
JP (1) JP6836510B2 (enExample)
AR (1) AR102781A1 (enExample)
DK (1) DK3229776T3 (enExample)
ES (1) ES2951598T3 (enExample)
FI (1) FI3229776T3 (enExample)
HU (1) HUE062561T2 (enExample)
LT (1) LT3229776T (enExample)
PL (1) PL3229776T3 (enExample)
PT (1) PT3229776T (enExample)
TW (1) TW201628654A (enExample)
WO (1) WO2016083343A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
MA38687A1 (fr) * 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
AU2015352685B2 (en) * 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
CN115137822B (zh) * 2022-06-13 2023-06-23 武汉大学中南医院 一种光热热电一体化的抗肿瘤植入体的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
DE69819519T2 (de) 1997-08-19 2004-09-23 Warner-Lambert Co. Llc Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2005086639A2 (en) 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
CA2697042A1 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
RU2013117288A (ru) 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
EP2670393B8 (en) * 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
WO2016083336A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações

Also Published As

Publication number Publication date
HUE062561T2 (hu) 2023-11-28
US20190374465A1 (en) 2019-12-12
EP3229776A1 (en) 2017-10-18
PT3229776T (pt) 2023-08-17
US20170258717A1 (en) 2017-09-14
ES2951598T3 (es) 2023-10-23
PL3229776T3 (pl) 2023-11-06
EP3229776B1 (en) 2023-06-28
FI3229776T3 (fi) 2023-08-15
US10391058B2 (en) 2019-08-27
DK3229776T3 (da) 2023-07-31
TW201628654A (zh) 2016-08-16
WO2016083343A1 (en) 2016-06-02
JP2018504450A (ja) 2018-02-15
LT3229776T (lt) 2023-08-25
AR102781A1 (es) 2017-03-22
US11471410B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
Izadiyan et al. Advancements in liposomal nanomedicines: innovative formulations, therapeutic applications, and future directions in precision medicine
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
US11471410B2 (en) Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
JP6789960B2 (ja) 医薬組成物、その調製及び使用
US20170258718A1 (en) Pharmaceutical composition, preparation and uses thereof
HK40115817A (en) Pharmaceutical composition, preparation and uses thereof
EA047692B1 (ru) Фармацевтическая композиция, ее получение и применения

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210205

R150 Certificate of patent or registration of utility model

Ref document number: 6836510

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250